Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

In vivo tumor growth of high-grade serous ovarian cancer cell lines

Open access
Mitra, Anirban K., Davis, David A., Tomar, Sunil, Roy, Lynn, Gurler, Hilal, Xie, Jia, Lantvit, Daniel D., Cardenas, Horacio, Fang, Fang, Liu, Yueying, Loughran, Elizabeth, Yang, Jing, Sharon Stack, M., Emerson, Robert E., Cowden Dahl, Karen D., V. Barbolina, Maria, Nephew, Kenneth P., Matei, Daniela, Burdette, Joanna E.·2015·Gynecologic Oncology

Abstract

Objective Genomic studies of ovarian cancer (OC) cell lines frequently used in research revealed that these cells do not fully represent high-grade serous ovarian cancer (HGSOC), the most common OC histologic type. However, OC lines that appear to genomically resemble HGSOC have not been extensively used and their growth characteristics in murine xenografts are essentially unknown. Methods To better understand growth patterns and characteristics of HGSOC cell lines in vivo, CAOV3, COV362, KURAMOCHI, NIH-OVCAR3, OVCAR4, OVCAR5, OVCAR8, OVSAHO, OVKATE, SNU119, UWB1.289 cells were assessed for tumor formation in nude mice. Cells were injected intraperitoneally (i.p.) or subcutaneously (s.c.) in female athymic nude mice and allowed to grow (maximum of 90 days) and tumor formation was analyzed. All tumors were sectioned and assessed using H&E staining and immunohistochemistry for p53, PAX8 and WT1 expression. Results Six lines (OVCAR3, OVCAR4, OVCAR5, OVCAR8, CAOV3, and OVSAHO) formed i.p xenografts with HGSOC histology. OVKATE and COV362 formed s.c. tumors only. Rapid tumor formation was observed for OVCAR3, OVCAR5 and OVCAR8, but only OVCAR8 reliably formed ascites. Tumors derived from OVCAR3, OVCAR4, and OVKATE displayed papillary features. Of the 11 lines examined, three (Kuramochi, SNU119 and UWB1.289) were non-tumorigenic. Conclusions Our findings help further define which HGSOC cell models reliably generate tumors and/or ascites, critical information for preclinical drug development, validating in vitro findings, imaging and prevention studies by the OC research community.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2015.05.040

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 213

Metadata

Authors
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Gurler, H., Xie, J., Lantvit, D. D., Cardenas, H., Fang, F., Liu, Y., Loughran, E., Yang, J., Sharon Stack, M., Emerson, R. E., Cowden Dahl, K. D., V. Barbolina, M., Nephew, K. P., Matei, D., & Burdette, J. E.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2015-08
Volume
138
Issue
2
Pages
372-377
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2105818146
Cited by
213
References
2
FWCI
17.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo tumor growth of high-grade serous ovarian cancer cell lines. https://app.cochat.ai/papers/10.1016/j.ygyno.2015.05.040
The paper
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Gurler, H., Xie, J., Lantvit, D. D., Cardenas, H., Fang, F., Liu, Y., Loughran, E., Yang, J., Sharon Stack, M., Emerson, R. E., Cowden Dahl, K. D., V. Barbolina, M., Nephew, K. P., Matei, D., & Burdette, J. E. (2015). In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2015.05.040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.